|
GenScript corporation
ova 254-262 ![]() Ova 254 262, supplied by GenScript corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/ova+254-262/ova+254+262/pmc06391875-81-19-22 Average 90 stars, based on 1 article reviews
ova 254-262 - by Bioz Stars,
2026-09
90/100 stars
|
Buy from Supplier |
Image Search Results
Journal: Journal of immunology (Baltimore, Md. : 1950)
Article Title: A Prime-Pull-Amplify Vaccination Strategy to Maximize Induction of Circulating and Genital-Resident Intraepithelial CD8 + Memory T Cells
doi: 10.4049/jimmunol.1800219
Figure Lengend Snippet: In situ TCR engagement promotes both recruitment of cognate and non-cognate activated CD8+ T cells. (A-D) CTV-labelled activated CD45.1+OT-I were pretreated or not with pertussis toxin and transferred to naïve C57BL/6 mice one day prior to ivag immunization with HPV PsV expressing OVA or a luciferase as a control. (A-B, E-F) CTV-labelled activated CD45.1+OT-I and Pmel-1 CD8+ T cells were co transferred to naïve C57BL/6 mice one day prior to ivag immunization with HPV PsV expressing OVA or a luciferase as a control. (B) In co-transfer condition, OT-I and Pmel-1 CD8+ T cells were distinguished by CD45.1 and H-2Kb/OVA257–264 tetramer staining. (C, E) On day 4 after immunization, absolute numbers and percent of OT-I and Pmel-1 CD8+ T cells were assessed in the cervicovaginal and dLN tissues, respectively. The mean absolute number and percentage of transferred OT-I CD8+ T cells per organs is shown as horizontal bar ± SD, each symbol represents an individual mouse. (D, F) Representative FACS plot of CD103 expression and CTV labeling on transferred OT-I CD8+ T from cervicovaginal and dLN tissues. Data are representative of two independent experiments (n=4–5 mice per group). P values (***P≤0.001, ****P≤0.0001) were determined by one-way ANOVA with post-hoc Tukey analysis.
Article Snippet: Spleen cells were incubated for three days at 37°C in RPMI medium containing recombinant human IL-2 (100IU/ml, TECIN) and
Techniques: In Situ, Expressing, Luciferase, Control, Staining, Labeling